Compare WCCB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WCCB | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.6M | 590.6M |
| IPO Year | 2026 | 2019 |
| Metric | WCCB | PHAT |
|---|---|---|
| Price | $61.16 | $7.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $67.00 | $20.45 |
| AVG Volume (30 Days) | 34.9K | ★ 1.2M |
| Earning Date | 09-23-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $6.43 | $80.58 |
| Revenue Next Year | $6.14 | $56.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $58.91 | $6.52 |
| 52 Week High | $61.95 | $18.31 |
| Indicator | WCCB | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 78.85 | 42.53 |
| Support Level | $59.77 | $6.91 |
| Resistance Level | $61.95 | $9.74 |
| Average True Range (ATR) | 0.88 | 0.36 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 55.39 | 56.06 |
West Coast Community Bancorp is a bank holding company. Through its banking subsidiary, it offers a full range of commercial and personal banking services to residents and businesses in Santa Cruz County and adjacent Monterey, San Luis Obispo, and Santa Clara counties. Its products and service offerings include mobile banking, credit and debit cards, treasury management, deposit products, such as checking, savings, and term certificate accounts, and lending products such as commercial, commercial real estate, construction, multifamily, municipal, asset-backed loans, etc. Its lending products also include various government guarantee programs such as Small Business Administration (SBA) and 504 programs, as well as U.S. Department of Agriculture (USDA) programs.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.